Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
Sergliflozin etabonate (1, 3, 10, 30 mg/kg; oral; once) significantly reduces non-fasting blood glucose levels in KK-Ay mice in a dose-dependent manner[1].
Sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate; fed; daily for 9 weeks) reduces non-fasting blood glucose level and decreases triglyceride content in the liver in a dose-dependent manner in KK-Ay mice[1].
References:
[1]. Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104.